Retrospective analysis of CA19-9 decrease in patients with metastatic pancreatic carcinoma (MPC) treated with FOLFIRINOX or gemcitabine (gem) in a randomized phase III study (ACCORD11/PRODIGE4)

Authors :: Olivier Bouché
Françoise Desseigne
Sophie Gourgou
Marc Ychou
Beata Juzyna
Jaafar Bennouna
Marta Jarlier
Thierry Conroy
Marie Robert
Source :: Journal of Clinical Oncology. 32:4115-4115
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 4115 Background: RECIST criteria remain the reference for tumor response evaluation. Carbohydrate antigen 19-9 (CA19-9) is known to be a sensitive and specific serum marker in pancreatic cancer. It...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Pathology
Metastatic Pancreatic Carcinoma
business.industry
FOLFIRINOX
medicine.disease
Tumor response
Gemcitabine
Internal medicine
Pancreatic cancer
medicine
Retrospective analysis
CA19-9
In patient
business
medicine.drug

Full Text Access

Tools